Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

IceCure Medical (ICCM) Net Cash Flow (2025 - 2026)

IceCure Medical has reported Net Cash Flow over the past 2 years, most recently at -$785000.0 for Q1 2026.

For Q1 2026, Net Cash Flow rose 47.03% year-over-year to -$785000.0; the TTM value through Mar 2026 reached -$2.3 million, down 52.97%, while the annual FY2025 figure was $1.2 million, 141.77% up from the prior year.
Net Cash Flow was -$785000.0 for Q1 2026 at IceCure Medical, up from -$1.5 million in the prior quarter.
Across five years, Net Cash Flow topped out at -$785000.0 in Q1 2026 and bottomed at -$1.5 million in Q1 2025.